Hims & Hers Health (NYSE:HIMS) shares climbed 2% on Wednesday following the announcement of its planned market entry into Canada in 2026, timed with the expected global debut of generic semaglutide.
The company’s Canadian rollout aims to coincide with the availability of lower-cost generic versions of the widely used weight loss drug, offering potentially significant savings compared to existing branded options. Currently, in Canada—where almost two-thirds of adults face overweight or obesity challenges—the branded semaglutide without clinical support carries a price tag exceeding C$200 per month, while generics are projected to be offered at a much lower cost.
This move builds on Hims & Hers’ recent acquisition of ZAVA, a digital health platform in Europe, reinforcing its strategy to grow internationally. Through its digital platform, Hims & Hers intends to deliver affordable treatment alternatives, alongside 24/7 access to licensed healthcare providers and customized care plans.
“Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,” said Andrew Dudum, co-founder and CEO of Hims & Hers. “As generic semaglutide becomes available for the first time globally, we’re focused on making it truly accessible, by combining affordability with trusted, personalized care at scale.”
The company views this expansion as a crucial step in its mission to increase healthcare accessibility, particularly in North America’s largest GLP-1 market where many patients still lack access to effective obesity therapies.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.